

# Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer

Join us to hear an international faculty of experts discuss approaches to tackling targets in cancer including MDM2-p53 antagonists in soft tissue sarcomas, HER2 inhibitors in NSCLC, and T-cell engagers in solid tumors.

**Friday, 20 October, 2023**  
**18:00-19:30 CEST**

**Oviedo Auditorium, Hall 7,  
IFEMA MADRID, Madrid, Spain**

**Chair: Charles Rudin, MD, PhD**

## Welcome and Introductions

**Charles Rudin, MD, PhD**

## Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma

**Patrick Schöffski, MD, MPH**

## Improving HER2 Targeting in NSCLC with Selective TKI

**Zofia Piotrowska, MD**

## T-cell Engagers: Fighting Solid Tumors from Within

**Charles Rudin, MD, PhD**

## Panel Discussion and Q&A

**Moderator: Charles Rudin, MD, PhD**

## Key Takeaways and Closing Remarks

**Charles Rudin, MD, PhD**